Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study.

Antonella D'arminio MonforteAlessandro TavelliMatteo SalaAnnalisa MondiStefano Rusconi Spinello AntinoriMassimo PuotiBenedetto Maurizio Celesia Lucia TaramassoAnnalisa SaracinoAndrea AntinoriAlessandro Cozzi-Leprinull null

Published in: The Journal of antimicrobial chemotherapy (2023)

In our cohort of PLWH treated with dolutegravir-based regimens and followed up for up to 4 years, we observed a low risk of treatment failure and no evidence for a difference by sex, after excluding discontinuation due to pregnancy concerns. However, we observed a higher risk of dolutegravir discontinuation for toxicity in women.

Keyphrases

hiv infected patients
antiretroviral therapy
pregnancy outcomes
polycystic ovary syndrome
oxidative stress
electronic health record
preterm birth
big data
machine learning
skeletal muscle
combination therapy
deep learning
artificial intelligence